[Assessment of the clinical and MRI results of the FREEDOMS and TRANSFORMS phase III. clinical trials].
Uzsoki Utcai Kórház, Budapest.
Gábor
G
Jakab
D000284:Administration, Oral; D017326:Clinical Trials, Phase III as Topic; D003226:Congresses as Topic; D003287:Contrast Media; D005062:European Union; D000068876:Fingolimod Hydrochloride; D005682:Gadolinium; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D016899:Interferon-beta / Q000008:administration & dosage / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging / Q000379:methods; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy* / Q000453:epidemiology / Q000276:immunology; D057175:Posters as Topic; D011409:Propylene Glycols / Q000008:administration & dosage / Q000627:therapeutic use*; D055502:Secondary Prevention; D013110:Sphingosine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013997:Time Factors; D017211:Treatment Failure; D016896:Treatment Outcome
D003287:Contrast Media; D007166:Immunosuppressive Agents; D011409:Propylene Glycols; D016899:Interferon-beta; D005682:Gadolinium; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine